Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Sales (P/S) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
An examination of short-term operating activity ratios reveals notable shifts over the observed period. Generally, a declining trend is apparent in several key efficiency metrics, particularly from the latter half of 2022 through 2025. This suggests a potential slowdown in the speed at which the business converts its assets into cash and manages its liabilities.
- Inventory Management
- Inventory turnover consistently decreased from 3.67 in April 2022 to 1.51 in December 2025. This indicates a lengthening of the time required to sell inventory. Correspondingly, the average inventory processing period increased from 99 days to 242 days over the same timeframe, suggesting a build-up of inventory and potential challenges in demand forecasting or inventory control. A slight recovery is observed in the final period, with the ratio increasing to 1.51.
- Receivables Management
- Receivables turnover exhibited a decline from 6.99 in April 2022 to 5.27 in December 2025. This suggests a slower collection of receivables. The average receivable collection period increased from 52 days to 69 days, indicating that it is taking longer to convert sales into cash. A temporary increase to 87 days is observed in September 2025, followed by a return to 69 days in December 2025.
- Payables Management
- Payables turnover generally decreased, moving from 6.66 in April 2022 to 3.07 in December 2025. This implies a lengthening of the time taken to pay suppliers. The average payables payment period increased from 55 days to 119 days, suggesting a potential strategy to conserve cash or a difficulty in meeting payment obligations. Fluctuations are present, with a peak of 98 days in December 2023.
- Overall Operating Cycle & Cash Conversion Cycle
- The operating cycle lengthened from 151 days in April 2022 to 311 days in December 2025, reflecting the combined effect of slower inventory turnover and receivable collection. The cash conversion cycle also increased, from 96 days to 192 days over the same period. This indicates a longer time between paying for inventory and receiving cash from sales. A significant outlier is observed in Working Capital Turnover in September 2024, reaching 5,036.00, which requires further investigation as it deviates substantially from other periods.
In summary, the observed trends suggest a deterioration in short-term operating efficiency. The increasing processing and collection periods, coupled with the declining turnover ratios, warrant further investigation to identify the underlying causes and implement corrective measures. The outlier in Working Capital Turnover in September 2024 should be examined to determine its validity and impact on overall financial performance.
Turnover Ratios
Average No. Days
Inventory Turnover
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Cost of sales | |||||||||||||||||||||
| Inventories | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Inventory turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Inventory turnover
= (Cost of salesQ4 2025
+ Cost of salesQ3 2025
+ Cost of salesQ2 2025
+ Cost of salesQ1 2025)
÷ Inventories
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The inventory turnover ratio demonstrates a generally declining trend over the observed period. Initially, the ratio fluctuated around 3.6, but subsequently decreased, reaching a low point in the latter half of the period before stabilizing slightly.
- Initial Period (Apr 3, 2022 – Dec 31, 2022)
- The inventory turnover ratio exhibited relative stability, ranging between 3.62 and 3.82. This suggests a consistent rate at which inventory was sold and replenished during this timeframe. Cost of sales varied considerably, but inventories remained relatively high, supporting the consistent turnover ratio.
- Declining Trend (Apr 2, 2023 – Sep 28, 2025)
- A noticeable downward trend in the inventory turnover ratio commenced in April 2023. The ratio decreased from 3.07 to a low of 1.46 in September 2025. This decline coincided with increasing inventory levels and, in some quarters, decreasing cost of sales. The most significant drops occurred between July 2023 and March 2024, and again between June 2024 and September 2025.
- Recent Stabilization (Dec 31, 2025)
- The ratio showed a slight increase to 1.51 in December 2025, potentially indicating a stabilization of inventory management practices. However, this remains significantly lower than the levels observed in the initial period. Cost of sales increased slightly in this period, while inventories decreased marginally.
The consistent decline in inventory turnover suggests a potential slowdown in the rate of sales relative to inventory levels. This could be attributable to various factors, including changes in demand, increased inventory holding costs, or inefficiencies in supply chain management. Further investigation into the underlying causes of this trend is warranted.
The fluctuations in cost of sales do not appear to fully explain the observed changes in inventory turnover, suggesting that inventory levels are playing a more significant role in the ratio’s movement.
Receivables Turnover
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Trade accounts receivable, net of allowance for doubtful accounts | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Receivables turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Receivables turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Trade accounts receivable, net of allowance for doubtful accounts
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The receivables turnover ratio exhibits fluctuations over the observed period, generally indicating a decreasing trend in the efficiency of collecting receivables, though with some quarterly variations. Initial values demonstrate a relatively stable turnover, followed by a period of decline and subsequent modest recoveries.
- Overall Trend
- From April 2022 through December 2023, the receivables turnover ratio generally decreased. Starting at 6.99, it declined to a low of 5.33 by the end of 2023. A slight upward movement is then observed through March 2024, but the ratio continues to fluctuate, ending at 5.27 in December 2025.
- Initial Period (Apr 3, 2022 – Dec 31, 2022)
- The ratio began at 6.99 and experienced a gradual decline to 6.21 by October 2022. A notable increase to 9.16 was observed in December 2022, potentially indicating a focused effort to accelerate collections or a seasonal impact on sales and receivables. This represents the highest value in the observed period.
- Subsequent Decline (Apr 2, 2023 – Sep 28, 2025)
- Following the peak in December 2022, the ratio decreased to 7.57 in April 2023, then remained relatively stable around 7.66 in July 2023. A more pronounced decline followed, reaching a low of 4.18 in September 2025. The final quarter shows a slight recovery to 5.27, but remains below the levels observed in the earlier part of the period.
- Recent Performance (Mar 30, 2025 – Dec 31, 2025)
- The most recent six months show a range between 4.40 and 5.27. The ratio in September 2025 (4.40) is the lowest recorded value, followed by a modest increase in the final quarter. This suggests potential challenges in maintaining consistent collection efficiency.
The fluctuations in receivables turnover correlate with changes in revenue, but the relationship is not always direct. Further investigation into credit policies, collection procedures, and customer payment behavior would be necessary to fully understand the drivers behind these trends.
Payables Turnover
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Cost of sales | |||||||||||||||||||||
| Trade accounts payable | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Payables turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Payables turnover
= (Cost of salesQ4 2025
+ Cost of salesQ3 2025
+ Cost of salesQ2 2025
+ Cost of salesQ1 2025)
÷ Trade accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The payables turnover ratio exhibits a generally declining trend over the observed period, punctuated by some quarterly fluctuations. Initially, the ratio decreased from 6.66 to 5.04 between April 2022 and December 2022. This initial decline suggests a lengthening of the time it takes to pay suppliers. Subsequently, the ratio experienced a modest recovery to 5.07 in October 2022, before falling to a low of 3.17 by December 2024. A slight increase is then observed through June 2025, but remains below the levels seen in the earlier part of the period.
- Overall Trend
- A consistent downward trend in payables turnover is apparent over the entire timeframe. The ratio decreased from 6.66 in April 2022 to 3.07 in December 2025, indicating a lengthening of the average time taken to settle outstanding obligations to suppliers.
- Short-Term Fluctuations
- While the overall trend is downward, there are noticeable quarterly variations. For example, a slight increase occurred between July 2023 (3.92) and October 2023 (5.07). These fluctuations may be attributable to changes in purchasing patterns, supplier negotiations, or shifts in payment terms.
- Relationship to Cost of Sales
- The decline in payables turnover does not appear directly correlated with the fluctuations in cost of sales. Periods of higher cost of sales do not consistently correspond to higher or lower payables turnover, suggesting factors beyond immediate purchasing activity are influencing payment practices. For instance, cost of sales increased from 3,237 to 9,269 between July 2023 and October 2023, while payables turnover increased from 3.92 to 5.07.
- Recent Performance
- The most recent quarters show a slight stabilization, with the ratio moving from 3.17 in December 2024 to 3.07 in December 2025. However, this remains significantly lower than the levels observed in the earlier periods, indicating that the company continues to take longer to pay its suppliers compared to the beginning of the analyzed timeframe.
The observed trend warrants further investigation to understand the underlying reasons for the lengthening payment cycle and its potential implications for supplier relationships and working capital management.
Working Capital Turnover
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Current assets | |||||||||||||||||||||
| Less: Current liabilities | |||||||||||||||||||||
| Working capital | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Working capital turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Working capital turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The working capital turnover ratio exhibits considerable fluctuation throughout the observed period. Initial values indicate a relatively strong turnover, which subsequently declines before experiencing significant volatility. A detailed examination reveals distinct phases in the ratio’s behavior.
- Initial Phase (Apr 3, 2022 – Dec 31, 2022)
- The working capital turnover ratio begins at 6.10 and generally decreases to 3.83 by October 2, 2022. A substantial increase is then observed, reaching 11.00 by December 31, 2022. This initial period suggests a decreasing efficiency in utilizing working capital, followed by a rapid improvement in the final quarter of the year. The increase in December 2022 is particularly noteworthy.
- Volatility and Decline (Apr 2, 2023 – Dec 31, 2023)
- The ratio experiences a sharp decline in the first half of 2023, falling from 6.89 to 2.03. This is followed by a further decrease to 1.62 and a negative working capital balance resulting in an undefined ratio for the final quarter of 2023. This period indicates a significant deterioration in the efficiency of working capital management and potentially challenges in liquidity.
- Extreme Fluctuation and Recovery Attempts (Mar 31, 2024 – Dec 31, 2025)
- The ratio demonstrates extreme volatility, with a value of 29.17 in the first quarter of 2024, followed by a missing value in the second quarter. A very high value of 5,036.00 is recorded in the third quarter of 2024, which is an outlier and warrants further investigation. Subsequent values range from 8.64 to 10.68, before settling at 10.58 by the end of 2025. This phase suggests attempts to improve working capital turnover, but with inconsistent results and the presence of an anomalous data point. The large value in September 2024 is likely due to a very small working capital balance, skewing the ratio.
Overall, the working capital turnover ratio demonstrates a lack of consistent performance. While periods of improvement are observed, they are interspersed with significant declines and volatility. The negative working capital in December 2023 and the outlier value in September 2024 require further scrutiny to understand the underlying causes and potential implications for the organization’s financial health.
Average Inventory Processing Period
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Inventory turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average inventory processing period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average inventory processing period exhibited a clear lengthening trend over the observed timeframe. Initially, the period remained relatively stable, fluctuating around 100 days in the first four quarters. However, a significant and sustained increase began in the first quarter of 2023 and continued through the third quarter of 2025.
- Initial Stability (Apr 3, 2022 – Dec 31, 2022)
- The average inventory processing period demonstrated minimal variation, ranging from 95 to 101 days. This suggests a consistent, predictable flow of inventory during this period.
- Accelerated Lengthening (Apr 2, 2023 – Sep 28, 2025)
- Starting in April 2023, the average inventory processing period began to increase substantially. It rose from 119 days to a peak of 251 days in September 2025. This indicates a slowing in the rate at which inventory is sold and replaced.
- Recent Moderation (Dec 31, 2025)
- The final reported period shows a slight decrease to 242 days, offering a potential indication that the lengthening trend may be stabilizing, although further observation is needed to confirm this.
- Correlation with Inventory Turnover
- The observed trend in the average inventory processing period is inversely correlated with the inventory turnover ratio. As the processing period lengthened, the inventory turnover ratio decreased, confirming that inventory is taking longer to convert into sales. The inventory turnover ratio declined from 3.67 to 1.51 over the period, reinforcing the conclusion of a slower inventory cycle.
The extended inventory processing period could be attributable to several factors, including decreased demand, increased inventory levels, supply chain disruptions, or changes in inventory management strategies. Further investigation would be required to determine the specific drivers behind this trend.
Average Receivable Collection Period
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Receivables turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average receivable collection period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average receivable collection period exhibited fluctuations over the observed timeframe. Initially, the period increased from 52 days to 59 days between April 2022 and October 2022, before decreasing significantly to 40 days by December 2022. Subsequent periods show a general increasing trend, peaking at 87 days in June 2024, followed by a decrease to 69 days by December 2025.
- Initial Trend (Apr 2022 - Oct 2022)
- An increasing trend in the average receivable collection period was observed during this period, rising from 52 days to 59 days. This suggests a potential slowing in the rate at which receivables were being collected, possibly due to changes in credit terms offered to customers or delays in customer payments.
- Significant Decrease (Oct 2022 - Dec 2022)
- A substantial decrease in the average collection period occurred between October 2022 and December 2022, falling from 59 days to 40 days. This indicates a marked improvement in the efficiency of collecting receivables, potentially resulting from focused collection efforts or a change in the customer mix.
- Subsequent Increase and Peak (Dec 2022 - Jun 2024)
- Following the December 2022 low, the average collection period generally increased, reaching a peak of 87 days in June 2024. This sustained increase suggests a re-emergence of challenges in collecting receivables, potentially linked to evolving economic conditions or shifts in customer payment behavior. The increase is gradual, but significant.
- Recent Fluctuations (Jun 2024 - Dec 2025)
- The period from June 2024 to December 2025 demonstrates volatility. The collection period decreased from 87 days to 69 days, indicating some improvement in collection efficiency. However, there was an intermediate peak of 83 days in September 2025, suggesting the improvement is not entirely consistent. The final value of 69 days represents a return to levels observed earlier in the timeframe.
Overall, the average receivable collection period demonstrates a cyclical pattern with periods of increase, significant decrease, and subsequent increases. The most recent data suggests a stabilization around 69 days, but continued monitoring is warranted to assess the sustainability of this trend.
Operating Cycle
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Operating cycle1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The operating cycle has demonstrated a generally increasing trend over the observed period. Analysis of the component ratios reveals the drivers behind this overall pattern. The average inventory processing period and average receivable collection period both contribute to the lengthening of the operating cycle.
- Average Inventory Processing Period
- The average inventory processing period exhibited a relatively stable pattern between April 2022 and December 2022, fluctuating between 95 and 101 days. A notable increase began in April 2023, rising to 158 days in July 2023 before moderating to 138 and 149 days in the subsequent quarters. This trend continued upward through the observed period, peaking at 251 days in September 2025, before decreasing slightly to 242 days by the end of the period. This suggests a potential slowdown in inventory turnover or an increase in the time required to process inventory.
- Average Receivable Collection Period
- The average receivable collection period showed more moderate fluctuations initially, ranging from 40 to 59 days between April 2022 and October 2022. A slight increase was observed in the subsequent quarters, stabilizing around 69-74 days through much of 2023 and early 2024. A more pronounced increase occurred in the latter half of 2024, reaching 87 days in September 2024, before decreasing to 69 days by December 2025. This indicates a potential lengthening in the time taken to collect payments from customers, although the recent decrease suggests a possible improvement.
- Operating Cycle
- The operating cycle, calculated as the sum of the average inventory processing period and the average receivable collection period, generally increased from 151 days in April 2022 to 311 days in December 2025. The most significant increase occurred between April 2023 and September 2025, driven by the increases in both component ratios. The peak of 334 days in September 2025 represents the longest operating cycle observed during the period, followed by a slight decrease to 311 days. This extended operating cycle implies that it is taking longer to convert investments in inventory and receivables into cash.
The combined effect of increasing inventory processing and receivable collection periods has resulted in a lengthening of the operating cycle. Continued monitoring of these ratios is recommended to identify the underlying causes of these trends and assess their potential impact on liquidity and overall financial performance.
Average Payables Payment Period
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Payables turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average payables payment period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average payables payment period exhibited a generally increasing trend over the observed period, though with notable quarterly fluctuations. Initially, the period stood at 55 days in April 2022, and progressively increased to 72 days by December 2022. Subsequent quarters reveal continued variability, with a peak of 119 days recorded in December 2025.
- Overall Trend
- From April 2022 through December 2025, the average payables payment period generally lengthened. While not consistently increasing each quarter, the overall direction points towards a slower rate of payment to suppliers. The period increased from 55 days to 119 days over the entire timeframe, representing an increase of 64 days or approximately 117%.
- Short-Term Fluctuations (2022-2023)
- The period increased from 55 days in April 2022 to 59 days in July 2022, then to 66 days in October 2022, and peaked at 72 days in December 2022. A slight decrease was observed in April 2023 (76 days), followed by a significant increase to 93 days in July 2023. The period then decreased to 72 days in October 2023 before rising sharply to 98 days in December 2023.
- Recent Performance (2024-2025)
- The period remained elevated in 2024, fluctuating between 87 and 115 days. A high of 115 days was recorded in December 2024. This trend continued into 2025, with the period reaching its highest point of 119 days in December 2025. The period was 110 days in March 2025 and 110 days in September 2025, indicating some stabilization around that level before the final increase.
The observed increases in the average payables payment period may suggest a deliberate strategy to manage cash flow by extending payment terms with suppliers. Alternatively, it could indicate challenges in maintaining timely payments, potentially due to liquidity constraints or operational inefficiencies. Further investigation would be required to determine the underlying cause of these trends.
Cash Conversion Cycle
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||
| Average payables payment period | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Cash conversion cycle1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The short-term operating activity, as measured by the cash conversion cycle and its components, exhibits notable fluctuations over the observed period. An overall lengthening of the cycle is apparent, particularly from late 2022 through 2025, though with some quarterly variations. The individual components – inventory processing, receivable collection, and payable payment – all contribute to this trend.
- Average Inventory Processing Period
- The average time to process inventory demonstrates a consistent upward trend. Starting at 99 days in April 2022, it generally increased, reaching a peak of 251 days in September 2025. While there are minor quarterly declines, the overall trajectory indicates a significant increase in the time required to convert inventory into finished goods and make them available for sale. The period stabilizes somewhat in the final quarter of 2025, decreasing to 242 days.
- Average Receivable Collection Period
- The average number of days to collect receivables also shows an increasing trend, though less pronounced than that of inventory processing. Beginning at 52 days, the collection period fluctuates but generally rises, peaking at 87 days in both the quarters ending in March 2024 and September 2025. A decrease is observed in the final quarter of 2025, falling to 69 days. This suggests a potential lengthening in the time taken to convert sales into cash, although with some quarterly volatility.
- Average Payables Payment Period
- The average time taken to pay suppliers also increases over the period. Starting at 55 days, the payment period generally extends, reaching a high of 119 days in December 2025. The period experiences fluctuations, but the overall trend indicates a lengthening of payment terms. This could be a strategic decision to manage cash flow, but also warrants monitoring for potential impacts on supplier relationships.
- Cash Conversion Cycle
- The cash conversion cycle, representing the total time funds are tied up in operations, generally increases from 96 days in April 2022 to 192 days in December 2025. The cycle experienced a dip to 63 days in December 2022, but subsequently increased. The most significant increases occur from late 2022 through 2024, with the cycle exceeding 200 days in several quarters. The final quarter of 2025 shows a slight decrease, but remains substantially higher than the initial period observed. This lengthening cycle suggests a need to evaluate operational efficiencies related to inventory management, receivables collection, and payables disbursement.
In summary, the observed trends indicate a growing operational cycle, driven by increases in all three component ratios. The most substantial driver appears to be the lengthening inventory processing period. Continued monitoring of these ratios is recommended to assess the impact on liquidity and overall financial health.